WO2014163400A1 - 도네페질을 포함하는 비경구투여용 약제학적 조성물 - Google Patents
도네페질을 포함하는 비경구투여용 약제학적 조성물 Download PDFInfo
- Publication number
- WO2014163400A1 WO2014163400A1 PCT/KR2014/002844 KR2014002844W WO2014163400A1 WO 2014163400 A1 WO2014163400 A1 WO 2014163400A1 KR 2014002844 W KR2014002844 W KR 2014002844W WO 2014163400 A1 WO2014163400 A1 WO 2014163400A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- donepezil
- microspheres
- biocompatible polymer
- release
- prepared
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to a composition for parenteral administration comprising Donepezil as an active ingredient and a method for preparing the same, comprising preparing Donepezil, which has been conventionally used for oral or transdermal, as a microparticle including a biodegradable biocompatible polymer and a release regulator.
- a pharmaceutical composition for sustained-release parenteral administration the drug is to be continuously released in vivo for 2 to 12 weeks or more, thereby reducing the frequency of administration to the patient and maintaining an effective concentration in the blood for a long time.
- Donepezil hydrochloride (donepezil hydrochloride) is widely used as a treatment for Alzheimer's disease having an acetylcholine esterase inhibitory effect, most of these anti-dementia drugs are administered orally in tablet form.
- the drug is appropriately selected depending on the disease or the nature of the drug and is administered to the patient in the form of tablets, capsules, syrups, granules, as well as injection, rectal and transdermal administration. Taking it is difficult.
- Pengcheng Zhang et al prepared and evaluated sustained-release microparticles of donepezil (Pengcheng Zhang, Lingli Chen, Wangwen Gu, Zhenghong Xu, Yu Gao, Yaping Li, In in vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease, Biomaterials, 28 (2007) 1882-1888). They prepared microspheres containing donepezil using a copolymer of lactide and glycolide, and the content of donepezil in the microspheres was 13.2%, so the drug loading rate was only 66%, and the drug loss was high. In order to do this, there is a problem that the dosage must be very large.
- An object of the present invention is to improve the compliance of the drug done with donepezil, to prepare a donepezil microparticles with a biocompatible polymer and a release control agent, to provide a sustained-release parenteral formulation having a stable drug release for a long time It is done.
- the donepezil microspheres of the present invention may further include a poorly soluble salt of donepezil as a release control agent, and examples of the poorly soluble salt used as the release control agent include xinapoate, nafadisylate and pamoate. .
- the biodegradable biocompatible polymer has an intrinsic viscosity of 0.5 to 1.9 dL / g, for example poly (lactide-co-glycolide), polylactide, polyglycolide, polycapro Lactone, gelatin, hyaluronate, or mixtures thereof, preferably at least one of polyglycolide, polylactide and polyglycolide and polylactide copolymers.
- polyglycolide and polylactide copolymers it is preferred that the molar ratio of lactide to glycolide is 50:50 to 90:10, most preferably 85:15.
- the donepezil microspheres of the present invention may have a size (D50) of 10 to 200 ⁇ m, and the donepezil content of the microspheres is preferably 15 to 50% by weight. If the amount of donepezil in the microspheres is less than 15% by weight, there is a problem of poor drug compliance due to an excessive dose, and when more than 50% by weight, drug release is accelerated, so that a sufficient sustained-release effect is not obtained.
- the donepezil release may last for 2 to 12 weeks or more.
- a step of washing the microspheres with a solvent such as ethanol may be added as necessary, whereby the initial release of donepezil can be suppressed.
- the present invention also provides a pharmaceutical composition for parenteral administration comprising donepezil microspheres comprising donepezil or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- a pharmaceutical composition for parenteral administration is especially an injection.
- Donepezil microspheres according to the present invention has a stable drug release for a long period of time can be maintained in the effective concentration of donepezil in the blood for 2 to 12 weeks or more, when prepared in parenteral administration formulations such as injections and safe Effectiveness can improve patient compliance.
- the prepared microspheres were washed several times with water for injection, followed by wet filtration using a sieve of 25 ⁇ m and 150 ⁇ m size and lyophilized for 64 hours.
- Xinapoic acid as a release regulator was added 1.0 equivalent to the donepezil base, and the remaining production method was carried out in the same manner as in Example 8 to prepare microspheres.
- the prepared microspheres were washed several times with water for injection and subjected to primary wet filtration using a 25 ⁇ m sieve.
- the obtained microspheres were washed with 25% (w / w) ethanol solution for 10 minutes at 20 ° C., and then subjected to secondary wet filtration using sieves of 25 ⁇ m and 150 ⁇ m and lyophilized for 64 hours.
- FIG. 1 is a photograph showing a SEM analysis result of measuring the form of donepezil microspheres according to each embodiment.
- 1A is Example 1
- FIG. 1B is Example 1-1
- FIGS. 1C-1H are Examples 2-7
- FIG. 1I is Example 2-1
- FIGS. 1J and 1K are Examples 8 and 8-, respectively.
- FIG. 1L and 1M are SEM photographs of the microspheres prepared in Example 9 and Example 9-1, respectively.
- microspheres About 100 mg of microspheres were put in a GC vial and dissolved in 10 mL of internal standard solution, and residual solvent was measured in the microspheres using GC.
- the column used was filled with G25 series, the inner diameter was 25m ⁇ 0.32mm, the film thickness 0.5 ⁇ m, 1 ⁇ l injection, the temperature was measured using a flame ionization detector at 250 °C.
- Diluent preparation 500 mg of mannitol, 50 mg of sodium carboxymethylcellulose, and 10 mg of polysorbate 80 were dissolved in purified water for injection to make 10 mL, and sodium hydroxide was added to prepare pH 7.0.
Abstract
Description
Claims (15)
- 도네페질 또는 그의 약제학적으로 허용되는 염을 포함하는 생분해성 생체 적합성 고분자로 이루어진 도네페질 미립구로서, 도네페질 함량이 15 중량% 이상인 미립구.
- 제 1 항에 있어서, 방출조절제로서 도네페질의 난용성 염을 추가로 포함하는 것을 특징으로 하는 도네페질 미립구.
- 제 2 항에 있어서, 도네페질의 난용성 염은 크시나포에이트, 나파디실레이트 또는 파모에이트인 것을 특징으로 하는 도네페질 미립구.
- 제 1 항에 있어서, 생분해성 생체 적합성 고분자는 고유점도가 0.5 내지 1.9 dL/g인 것을 특징으로 하는 도네페질 미립구.
- 제 1 항에 있어서, 생체 적합성 고분자는 폴리(락타이드-코-글리콜라이드), 폴리락타이드, 폴리글리콜라이드, 폴리카프로락톤, 젤라틴, 히알루로네이트, 또는 이들의 혼합물인 것을 특징으로 하는 도네페질 미립구.
- 제 5 항에 있어서, 생체 적합성 고분자가 폴리글리콜라이드, 폴리락타이드 및 폴리글리콜라이드와 폴리락타이드 공중합체 중의 적어도 하나인 것을 특징으로 하는 도네페질 미립구.
- 제 6 항에 있어서, 생체 적합성 고분자가 폴리글리콜라이드와 폴리락타이드 공중합체로 락타이드 대 글리콜라이드의 몰비가 50:50 내지 90:10인 것을 특징으로 하는 도네페질 미립구.
- 제 7 항에 있어서, 폴리글리콜라이드와 폴리락타이드 공중합체로 락타이드 대 글리콜라이드의 몰비가 85:15인 것을 특징으로 하는 도네페질 미립구.
- 제 1 항에 있어서, 크기(D50)가 10 내지 200 ㎛인 것을 특징으로 하는 도네페질 미립구.
- 제 1 항에 있어서, 미립구 중 도네페질 함량은 15 내지 50 중량%인 것을 특징으로 하는 도네페질 미립구.
- 제 1 항에 있어서, 도네페질 방출이 2주 내지 12주 이상 지속되는 것을 특징으로 하는 도네페질 미립구.
- 도네페질 또는 그의 약제학적으로 허용되는 염 및 생분해성 생체적합성 고분자를 1종 이상의 용매에 용해시키는 단계;상기 도네페질 및 생분해성 생체적합성 고분자의 용액을 친수성 고분자 수용액에 넣고 교반하여 미립구를 형성시키는 단계; 및용매를 제거하는 단계를 포함하는, 제 1 항에 따른 도네페질 미립구의 제조 방법.
- 제 12 항에 있어서, 미립구를 세척하는 단계가 추가되는 것을 특징으로 하는 제조방법.
- 제 1 항에 따른 도네페질 미립구 및 약제학적으로 허용되는 담체를 포함하는 비경구투여용 약제학적 조성물.
- 제 14 항에 있어서, 주사제인 것을 특징으로 하는 약제학적 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/782,276 US10085941B2 (en) | 2013-04-03 | 2014-04-02 | Pharmaceutical composition for parenteral administration, containing donepezil |
JP2016506237A JP2016515612A (ja) | 2013-04-03 | 2014-04-02 | ドネペジルを含む非経口投与用の医薬組成物 |
CN201480020234.0A CN105338966A (zh) | 2013-04-03 | 2014-04-02 | 包含多奈哌齐的非口服用药物组合物 |
CA2908248A CA2908248A1 (en) | 2013-04-03 | 2014-04-02 | Pharmaceutical composition for parenteral administration, containing donepezil |
EP14779696.5A EP2982367B1 (en) | 2013-04-03 | 2014-04-02 | Pharmaceutical composition for parenteral administration, containing donepezil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0036292 | 2013-04-03 | ||
KR1020130036292A KR101811797B1 (ko) | 2013-04-03 | 2013-04-03 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163400A1 true WO2014163400A1 (ko) | 2014-10-09 |
Family
ID=51658625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002844 WO2014163400A1 (ko) | 2013-04-03 | 2014-04-02 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10085941B2 (ko) |
EP (1) | EP2982367B1 (ko) |
JP (1) | JP2016515612A (ko) |
KR (1) | KR101811797B1 (ko) |
CN (1) | CN105338966A (ko) |
CA (1) | CA2908248A1 (ko) |
WO (1) | WO2014163400A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3705116A4 (en) * | 2017-11-01 | 2021-08-04 | Korea Research Institute of Chemical Technology | MICROSPHERICAL RETARD INJECTION WITH ESCITALOPRAM AND METHOD OF MANUFACTURING IT |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11197850B2 (en) | 2017-02-23 | 2021-12-14 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor |
KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
RU2731489C1 (ru) * | 2017-11-30 | 2020-09-03 | Джи2Джибио, Инк. | Препарат для инъекций с замедленным высвобождением с содержанием донепезила и способ получения такого препарата |
KR102047983B1 (ko) * | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
KR102091114B1 (ko) * | 2017-12-26 | 2020-03-19 | 동국제약 주식회사 | 도네페질을 포함하는 장기지속형 미립구 및 이의 제조방법 |
KR102224918B1 (ko) * | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법 |
KR102272756B1 (ko) * | 2018-09-11 | 2021-07-05 | 주식회사 메디폴리머 | 정신질환 또는 중추신경계 질환 치료용 서방형 약물전달 제형 및 이의 제조방법 |
AU2019401868B2 (en) * | 2018-12-17 | 2023-07-27 | G2Gbio, Inc. | Sustained-release injection comprising deslorelin, and preparation method therefor |
KR101980534B1 (ko) * | 2019-04-05 | 2019-05-21 | 주식회사 종근당 | 도네페질 미리스틸옥시메틸에테르 또는 이의 약제학적으로 허용가능한 염 |
JP7301448B2 (ja) * | 2019-05-31 | 2023-07-03 | エルジー・ケム・リミテッド | カスパーゼ阻害剤プロドラッグを含有する注射用組成物及びその調製方法 |
EP3970699A4 (en) * | 2019-05-31 | 2022-08-10 | LG Chem, Ltd. | COMPOSITION FOR CASPASE INHIBITOR PRODRUG INJECTION |
AU2020312361A1 (en) * | 2019-07-12 | 2022-03-03 | G2Gbio, Inc. | Long-lasting formulation containing rivastigmine, and method for preparing same |
US20230096928A1 (en) * | 2020-02-14 | 2023-03-30 | G2Gbio, Inc. | Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof |
KR102593114B1 (ko) * | 2020-05-11 | 2023-10-24 | 주식회사 아울바이오 | 약물 봉입률과 지속방출능력이 향상된 미립구 및 이의 제조방법 |
KR20210158232A (ko) * | 2020-06-23 | 2021-12-30 | 주식회사 아울바이오 | 치매치료를 위한 장기지속형 주사제 |
KR102652905B1 (ko) * | 2021-08-09 | 2024-04-01 | 주식회사 메디폴리머 | 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트 |
KR20240000404A (ko) * | 2022-06-23 | 2024-01-02 | 주식회사 지투지바이오 | 도네페질과 파모산을 함유하는 서방성 미립구 |
KR20240000405A (ko) * | 2022-06-23 | 2024-01-02 | 주식회사 지투지바이오 | 약물과 파모산을 함유하는 서방성 미립구 |
CN115569122A (zh) * | 2022-10-20 | 2023-01-06 | 深圳善康医药科技股份有限公司 | 一种多奈哌齐缓释植入剂及其制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100961413B1 (ko) * | 2001-06-29 | 2010-06-09 | 다케다 야쿠힌 고교 가부시키가이샤 | 제어 방출 조성물 및 이의 제조 방법 |
KR20100094227A (ko) * | 2009-02-18 | 2010-08-26 | 동국제약 주식회사 | 서방출성 미립구의 제조방법 |
KR20120011344A (ko) * | 2010-07-21 | 2012-02-08 | 에스케이케미칼주식회사 | 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구 |
KR20120093293A (ko) * | 2009-10-21 | 2012-08-22 | 데이고꾸세이약꾸가부시끼가이샤 | 도네페질 함유 경피 흡수형 제제 |
KR20120122558A (ko) * | 2011-04-29 | 2012-11-07 | 주식회사 바이오파마티스 | 도네페질 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6113683A (ja) * | 1984-06-28 | 1986-01-21 | Oki Electric Ind Co Ltd | 半導体レ−ザ及びその製造方法 |
JPH10203966A (ja) | 1996-11-21 | 1998-08-04 | Takeda Chem Ind Ltd | 徐放性マイクロカプセルおよびその製造法 |
EP1262189A1 (en) * | 2000-03-06 | 2002-12-04 | Sumitomo Pharmaceuticals Company, Limited | Leptin-resistance ameliorating agents |
ATE404170T1 (de) * | 2003-03-14 | 2008-08-15 | Debio Rech Pharma Sa | Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems |
HUP0401850A3 (en) * | 2004-09-15 | 2008-03-28 | Egis Gyogyszergyar Nyilvanosan | Donepezil salts for producing pharmaceutical composition |
MX2009003737A (es) * | 2006-10-05 | 2009-06-16 | Panacea Biotec Ltd | Composicion inyectable en deposito y su procedimiento de preparacion. |
US20130280330A9 (en) | 2009-07-31 | 2013-10-24 | Xi'an Libang Medical Technology Co., Ltd. | Microsphere drug carrier, preparation method, composition and use thereof |
US20140243278A1 (en) * | 2011-07-05 | 2014-08-28 | Sunil Sadanand Nadkarni | Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof |
WO2013078608A1 (en) * | 2011-11-29 | 2013-06-06 | Ziqiang Gu | Donepezil pamoate and methods of making and using the same |
-
2013
- 2013-04-03 KR KR1020130036292A patent/KR101811797B1/ko active IP Right Grant
-
2014
- 2014-04-02 CA CA2908248A patent/CA2908248A1/en not_active Abandoned
- 2014-04-02 EP EP14779696.5A patent/EP2982367B1/en active Active
- 2014-04-02 WO PCT/KR2014/002844 patent/WO2014163400A1/ko active Application Filing
- 2014-04-02 US US14/782,276 patent/US10085941B2/en active Active
- 2014-04-02 CN CN201480020234.0A patent/CN105338966A/zh active Pending
- 2014-04-02 JP JP2016506237A patent/JP2016515612A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100961413B1 (ko) * | 2001-06-29 | 2010-06-09 | 다케다 야쿠힌 고교 가부시키가이샤 | 제어 방출 조성물 및 이의 제조 방법 |
KR20100094227A (ko) * | 2009-02-18 | 2010-08-26 | 동국제약 주식회사 | 서방출성 미립구의 제조방법 |
KR20120093293A (ko) * | 2009-10-21 | 2012-08-22 | 데이고꾸세이약꾸가부시끼가이샤 | 도네페질 함유 경피 흡수형 제제 |
KR20120011344A (ko) * | 2010-07-21 | 2012-02-08 | 에스케이케미칼주식회사 | 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구 |
KR20120122558A (ko) * | 2011-04-29 | 2012-11-07 | 주식회사 바이오파마티스 | 도네페질 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 |
Non-Patent Citations (2)
Title |
---|
MD , S. ET AL.: "Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 40, no. 2, 1 February 2013 (2013-02-01), pages 278 - 287, XP055285164 * |
PENGCHENG ZHANG; LINGLI CHEN; WANGWEN GU; ZHENGHONG XU; YU GAO; YAPING LI: "In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease", BIOMATERIALS, vol. 28, 2007, pages 1882 - 1888, XP005856384, DOI: doi:10.1016/j.biomaterials.2006.12.016 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3705116A4 (en) * | 2017-11-01 | 2021-08-04 | Korea Research Institute of Chemical Technology | MICROSPHERICAL RETARD INJECTION WITH ESCITALOPRAM AND METHOD OF MANUFACTURING IT |
Also Published As
Publication number | Publication date |
---|---|
KR20140120496A (ko) | 2014-10-14 |
CN105338966A (zh) | 2016-02-17 |
CA2908248A1 (en) | 2014-10-09 |
US10085941B2 (en) | 2018-10-02 |
EP2982367B1 (en) | 2019-11-27 |
JP2016515612A (ja) | 2016-05-30 |
US20160022583A1 (en) | 2016-01-28 |
EP2982367A4 (en) | 2016-08-24 |
EP2982367A1 (en) | 2016-02-10 |
KR101811797B1 (ko) | 2017-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014163400A1 (ko) | 도네페질을 포함하는 비경구투여용 약제학적 조성물 | |
WO2015020240A1 (ko) | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 | |
WO2010024615A2 (ko) | 용매교류증발법에 의한 서방출성 미립구의 제조방법 | |
WO2018221884A1 (ko) | 방출제어가 용이한 서방성 약물 미립자의 제조방법 | |
AU2413099A (en) | Novel suppository form comprising an acid-labile active compound | |
WO2021010719A1 (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
WO2016021835A1 (ko) | 약물 함유 서방성 미립자의 제조 방법 | |
WO2021187842A1 (ko) | 사스 코로나바이러스 감염증 치료용 약학 제제 및 이의 의약 용도 | |
WO2021091333A1 (ko) | 지속 방출을 위한 마이크로스피어 및 이의 제조 방법 | |
WO2013147452A1 (en) | Pharmaceutical composition in form of non-aqueous liquid comprising revaprazan or its salt | |
WO2021125797A1 (ko) | 올라파립의 용해도 및 생체이용율이 개선된 조성물 | |
WO2012148181A2 (ko) | 약물 방출제어용 조성물 | |
WO2016013795A1 (ko) | 서방성 제제 | |
KR20130100464A (ko) | 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물 | |
WO2021133051A1 (ko) | 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물 | |
WO2022119300A1 (ko) | 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물 | |
WO2011031100A2 (en) | Aripiprazole-bentonite-aea hybrid, pharmaceutical composition containing the same and method for preparing the same | |
WO2018203636A1 (ko) | 수용해도 및 생체이용율이 개선된 조성물 | |
WO2020080875A1 (ko) | 아프레피탄트의 경구용 조성물 | |
WO2015163689A1 (ko) | 활성 성분 (i) 함유 조성물 및 이의 제조 방법 | |
WO2019107989A1 (ko) | 피마살탄을 포함하는 고체 분산체 | |
WO2014030913A1 (ko) | 폴리(4-하이드록시부티레이트)-b-모노메톡시(폴리에틸렌글리콜) 공중합체 나노입자, 이의 제조방법 및 이를 유효성분으로 함유하는 뇌질환 치료용 약학적 조성물 | |
WO2016137266A2 (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
WO2023249461A1 (ko) | 도네페질과 파모산을 함유하는 서방성 미립구 | |
WO2014142521A1 (ko) | 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480020234.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14779696 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2908248 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016506237 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14782276 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014779696 Country of ref document: EP |